Michael Chang

Michael joined the Adjuvant investment team from the Bill & Melinda Gates Foundation (BMGF) where he worked with its Global Health Division and Strategic Investment Fund to structure investments into biotech companies, leading academic centers, and other non-profit organizations that have the goal of stimulating technological innovation in global health. Michael has experience investing in the development of drugs, vaccines, diagnostics, and health data solutions across a range of high-burden and neglected disease areas.

Before joining BMGF, Michael spent several years covering the specialty pharmaceuticals sector as an equity research analyst at Piper Jaffray in New York. Michael started his career in the investment banking practice at Stifel where he focused on mergers and acquisitions advising. He earned a BA in International Relations from Johns Hopkins University.